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Abstract
While a known link between prenatal cannabis exposure and anencephaly exists, the relationship of prenatal
cannabis exposure with neural tube defects (NTDs) generally has not been defined. Published data from Canada
Health and Statistics Canada were used to assess this relationship. Both cannabis use and NTDs were shown to
follow an east-west and north-south gradient. Last year cannabis consumption was significantly associated (P <
.0001; cannabis use–time interaction P < .0001). These results were confirmed when estimates of termination
for anomaly were used. Canada Health population data allowed the calculation of an NTD odds ratio) of 1.27
(95% confidence interval = 1.19-1.37; P < 10−11) for high-risk provinces versus the remainder with an attributable
fraction in exposed populations of 16.52% (95% confidence interval = 12.22-20.62). Data show a robust positive
statistical association between cannabis consumption as both a qualitative and quantitative variable and NTDs on
a background of declining NTD incidence. In the context of multiple mechanistic pathways these strong statistical
findings implicate causal mechanisms.
Keywords
cannabinioids, anencephalus, spina bifida cystica, cannabis, neural tube defects
Received April 24, 2019. Received revised October 23, 2019. Accepted for publication November 19, 2019.

Introduction
Neural tube closure defects (NTDs) are usually understood to include lumbosacral myelomeningocele, anencephaly (including exencephaly, cranioraschisis, and
acrania), and encephalocele together with a variety of
rarer severe defects.1,2 They are responsible for an estimated 300 000 major congenital anomalies worldwide
annually, and approximately 88 000 deaths and 8.6 million disability-adjusted life years across the globe.3 They
are a major cause of death in small children under 5
years of age.
A number of risk factors have been identified for
NTDs including maternal obesity, diabetes, especially
poorly controlled insulin-dependent diabetes, vitamin
B12 deficiency, some genetic anomalies of the folic acid
metabolism pathway, and the use of some drugs.4-6
Gestational use of a variety of drugs has been associated
with increased rates of NTDs including anticonvulsants

(carbamazepine, phenytoin, valproic acid), antidepressants (sertraline, fluoxetine), mood stabilizers (lithium),
and folic acid antagonists (methotrexate, trimethoprim).7,8
Hence, these drugs are relatively contraindicated during
parturition and are only used in selected cases where it is
felt that the benefits outweigh the known risks.
Dietary supplementation with folic acid has been
shown to dramatically reduce the incidence of NTDs by
up to 72% in 3 randomized controlled trials from the
United States, China, and Europe.9-11 This has rightly
been hailed as one of the major neonatal public health
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triumphs of our time and places NTDs fairly in the group
of largely preventable disorders. Unfortunately, their
rate continues to be very high in some of the less developed parts of the world, with rates exceeding 50 cases/10
000 live births in parts of India, Africa, the Middle East,
and up to 200/10 000 in some of the northern regions of
China.3,12,13
The practice of therapeutic early termination of pregnancy for anomaly (ETOPFA) has also been rising from
1980 to the present time in many places including the
Canadian province of British Colombia,14 Sweden,15
Europe,16 the United States,17 and Western Australia18
and is thought to be the primary cause of the falling rates
of NTDs in various registries.16-19 The issue is very
important in relation to NTDs as ETOPFA rates of 80%
have been reported for anencephaly, 46% for spina
bifida, and 56% for encephalocoele in Canada in recent
years.1 Therefore, epidemiological studies that consider
data for live births may miss 80% to 90% of the true
defect rate in some congenital anomaly registries.18
The incidence of NTDs in Canada as a function of
births (= stillbirths plus live births but excluding
ETOPFAs) dropped from 1989 to 2007 from a mean of
11.1 to 4.1/10 000 births.20,21
It is said to be difficult to differentiate the relative
contribution of dietary folic acid supplementation compared with ETOPFA as an explanation for the falling
rates of NTDs in Canada.20
Interestingly, several papers have been issued by the
National Birth Defects Prevention Network (NBDPN)
of the Centers for Disease Control and Prevention
(CDC) Atlanta, Georgia, which have noted that the rate
of anencephaly is almost doubled after cannabis exposure.22,23 It is well known that cannabis is the most commonly used illicit drug with 183 million individuals
worldwide reporting its use.24-26 Indeed, 161 000 pregnant women in the United States reported cannabis use
while pregnant,27-29 24% of pregnant Californian teenagers tested positive for cannabinoids,30 and indeed in
69% of cases cannabis dispensaries in Colorado recommend the use of cannabis to pregnant mothers.31
Cannabis use by females in Canada rose from 7% in
2013 to 10% in 2015.32 Canadian data show that 72%
most of the cannabis users who have used cannabis in
the last year have used it in the previous 3 months.33 All
4 of the National Cannabis Surveys conducted by
Statistics Canada in 2018 show that cannabis is used
overwhelmingly and disproportionately by young adults
in the reproductive age group.33 Cannabis edibles are
used by 41% of females in the preceding 3 months compared with only 26% of males, representing a 1.57-fold
higher rate of use.32 Hence, cannabis use during pregnancy is a major public health issue. And as noted above,
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anencephalus is one of the classical NTDs. These data
broaden the context of the cannabis-anencephalus link,
which has been reported several times by the CDC from
a closely constrained discussion of anencephalus alone
and places it in the wider context of NTDs generally
since they all share a similar pathophysiology in terms
of the zipper-like closure of the neural tube during early
fetal development.
This sets up an interesting dichotomy of population
health forces in the child-bearing population with folic
acid augmentation on the one hand tending to reduce
NTDs and drug use on the other tending to increase them.
Canada forms a promising nation in which to study
the public health implications of these issues as data pertaining to both NTD incidence and cannabis use has been
made available. The Canadian government recently published large reviews of the national experience of NTDs
and a number of surveys document drug use by the
Canadian populace at the provincial level. Indeed, one
survey suggests a 3-fold variation in cannabis use across
Canadian provinces from 11% in Quebec to 33% in
Nunavut.34 Significant variance in each parameter separately naturally raises the issue of the extent to which the
observed variation in cannabis use accounts for the
observed variation in NTD incidence. This forms an
ideal opportunity to study these modern neonatal epidemiological-ecological trends at the associational level.
This study was performed to examine the relationship between cannabis use and NTD incidence to determine if the causal relationship previously identified by
the National Birth Defects Prevention Network
(NBDPN) of the CDC in relation to anencephaly22,23
could be identified in the national teratological profile of
NTDs in Canada.

Methods
Data Sources
Data on neural tube defect rates excluding terminations
for defects by province was taken from a Canadian government publication (Tables B3.2A, B3.2B, B3.2C,
pages 106-107, in Public Health Agency of Canada,
Health Canada35). Data for NTD rates by province
including termination for defects for the same 3 periods
was taken from Supplementary Table 2 in De Wals et al.1
Data on cannabis use were taken from 2 sources. The
University of Waterloo performed a commissioned survey of Canadian provinces for Canada Health.36 Statistics
Canada has also performed surveys of Canadian cannabis use by province and territory.34 The survey for the
second quarter of 2018 had complete data for all Canadian
provinces and territories.34
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Cannabis Use Group Allocation
The 5 highest provinces in the University of Waterloo
dataset were assigned to high cannabis states, namely,
Newfoundland, Prince Edward Island, Nova Scotia,
Manitoba, and Saskatchewan. Statistics Canada indicated that the provinces of Newfoundland, Nova Scotia,
and Ontario were in the high-use group together with the
territories of Nunavut, Northwest, and Yukon.

ETOPFA Estimation
The existence of a dataset for Canadian NTDs with
ETOPFAs included1 and one without20 covering very
similar time periods clearly provide an opportunity to
derive the applicable ETOPFA rates by period from the
difference between these 2 rates. The arithmetical details
for these calculations are shown in Supplementary Table
1 (available online). From these data one is able to
derive an average ETOPFA rate in each of the 3 periods.
Since the data for Prince Edward Island is incomplete in
Health Canada,20 this data point was omitted in calculating the average for the 3 periods.

Statistics
Data were processed in “R” v3.5.2 and “R Studio”
v1.1.463 from the Central “R” Archive Network. Graphs
and maps were drawn in “ggplot”. Data were log transformed to improve compliance with normality assumptions based on the results of the Shapiro-Wilks test. Risk
ratios were calculated using the “epiR” package. P <
.05 was considered significant.

Ethical Approval
Ethical approval for this study was received from the
Human Research Ethics Committee (HREC) of the
Southcity Medical Centre and the University of Western
Australia. The approval from Southcity Medical Centre
was dated May 31, 2018, and the approval from the
University of Western Australia was dated April 1, 2019,
and numbered RA/4/20/4724.

Results
A total of 3919 cases of NTDs were recorded from 1991
to 2007 among 6 092 250 live births in the Health
Canada Reference report.35
Folic acid augmentation into the grain staples in Canada
commenced in 1997 and became mandatory in September
2000. Hence, the NTD incidence data across this period
naturally falls into 3 periods: before, during, and after this
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transitional period. Figure 1 maps the distribution of cannabis use in 2015 and of NTDs in the 3 periods from 1991
to 1996, 1997 to 2000, and 2001 to 2007 across Canada.
One notes that these datasets relate to differing time
periods. While this is an issue, survey data of cannabis
use prevalence across Canada is very rare and this
University of Waterloo survey is the earliest dataset we
were able to identify. It is used here as we feel that due
to spatiotemporal autocorrelation whatever cannabis use
was at an earlier time period was related in some manner
to cannabis use at this earliest documented period.
Figure 2A presents a scatterplot of the NTD rate by
time. Data have been horizontally “jittered” to prevent
overplotting, and data points are positioned about the
midpoint of the 3 intervals: 1991 to 1996, 1997 to 2000,
and 2001 to 2007. The highest levels of NTD s occurred
in Newfoundland and Nova Scotia in the 1991 to 1996
period, with NTD rates of 30.5 and 19.8/10 000, respectively. The obvious downward trend over time is clear.
Figure 2B re-plots these data after dividing the provinces into high and low cannabis use areas ranked from
the University of Waterloo survey of 2014-2015.36 A
clear separation of the high and low cannabis use provinces is apparent. Figure 2C does the same thing following the assignment distribution of Statistics Canada for
2018.34 One notes in Figure 2B and C that the incidence
of NTDs in both high- and low-prevalence provinces is
similar in 2004. This appears to be due to a greater
reduction in the high cannabis use provinces and territories than in the low prevalence areas; however, in the
absence of accurate ETOPFA data one cannot be sure if
an increase in ETOPFA practice might also have been
implicated. Again Figure 2C shows a clear separation of
the 2 regression lines. This is quantified in the Table 1
where cannabis use in 2015 is shown to be significant (P
= .0063), and for cannabis use in 2018 both cannabis
use itself, and cannabis use in interaction with time are
shown to be highly significant (both P < .0001).
Figure 3 graphs the NTD rates against (1) last year
cannabis use; (2) age of initiation of cannabis use; and (3)
an index that is derived as the percent of cannabis use
divided by the age of initiation for the University of
Waterloo data.36 Close examination of panel A shows that
the scales in each of the 3 graphs is falling, consistent
with the drop in overall levels of NTDs by each period. In
the middle panels it appears that rising age of initiation is
associated with falling rates of NTDs; however, these
changes are not significant. Results for the Cannabis
Index parallel those for the percent cannabis use.
These various effects are quantified in Table 1. One
notes that when the whole dataset is considered together
there are many highly significant terms involving cannabis use relating to group assignment, last month and
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Figure 1. Maps of cannabis and neural tube defect (NTD) distribution. (A) Last year cannabis use rates by province, 2015. (B)
NTD rates by province from 1991 to 1996. (C) NTD rates by province from 1997 to 2000. (D) NTD rates by province from
2001 to 2007.

last year cannabis use, age of initiation, and the cannabis
index all in 2015, and cannabis use in 2018 both as a
qualitative variable by way of group assignment and as
a quantitative continuous variable.
As noted above, Gilbert et al20 the Canadian provincial NTD data without ETOPFAs and1 lists the same
dataset with ETOPFAs included. The difference in these
2 rates therefore logically represents the rate of ETOPFA
for NTDs in the various listed Canadian provinces. Data
from external sources indicate that the NTD rate has
been relatively constant and stable in Canada prior to
and after the transitional period of the introduction of
folic acid.20,21 Supplementary Table 1 provides the arithmetical details of how these calculations were performed. Informatively one notes that the average
ETOPFA rate in the 3 periods rose from 32.56% in the
first period, to 35.05% and 43.74% in the second and
third periods, respectively. These average rates were
then used to estimate an NTD rate inclusive of ETOPFAs

for Saskatchewan, Ontario, and New Brunswick, whose
data were not provided.1
These estimates of the NTD rates including the
ETOPFA rate were then regressed against cannabis use
variables with the highly significant results (Table 2).
Data presented Public Health Agency of Canada,
Health Canada,35 allow one to calculate the birth populations at risk. When populations were divided based on
the University of Waterloo dataset it is calculated that
1096 of 1 423 104 births had NTDs in high-risk states
and 2823 of 4 667 146 births in low cannabis using
states had NTDs, which provides a point estimate for
the odds ratio (OR) of 1.274 (95% confidence interval
[CI] = 1.19-1.37, P = 9.19 × 10−12). This is equivalent
to an attributable risk in the exposed population of
16.52% (95% CI = 12.22% to 20.62%). When provinces were assigned based on the Statistics Canada
grouping, very similar results were obtained (OR = 1.25,
95% CI = 1.16-1.35, P = 2.47 × 10−9), attributable
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Figure 2. Neural tube defect rates over time. (A) Neural tube defect rates over time overall data. (B) Neural tube defect
rates over time by high and low cannabis use provinces (2015 data). (C) Neural tube defect rates over time by high and low
cannabis use provinces (2018 data).

risk in exposed population of 16.35% (95% CI =
11.40% to 21.01%).

Discussion
This study shows that, notwithstanding the overall positive response of the maternal population to folic acid

supplementation there are statistical associational signals within the Canadian perinatal teratological data on
NTDs indicating a positive relationship to cannabis use.
Highly statistically significant relationships between
NTD incidence both in relation to birth defect rates, and
also after correction for estimates of the effect of early
abortions for defects were studied, and the relationship
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Table 1. Linear Regressions of Live Born Neural Tube Defect (NTD) Rates.
Parameter Analyses
Input Parameters
NTD rate by cannabis use by era
Era 1
Cannabis use (annual)
Era 2
Cannabis use (annual)
Era 3
Cannabis use (annual)
NTD rate by cannabis use by time and
parameter
Rate ~ year * group (2015)
Year
Group
Rate ~ year * cannabis use (annual)
Year
Cannabis use (annual)
Rate ~ year * cannabis use (month)
Year
Cannabis use (month)
Rate ~ year * age initiation
Year: age initiation
Age initiation
Rate ~ year * cannabis index
Year
Cannabis index
Rate ~ year * group (2018)
Year
Group
Year: group
Rate ~ year * cannabis use (3 months, 2018)
Cannabis use (3 months)
Year: cannabis use (3 months)

Model Parameters

SE

t Value

Pr(>|t|)

Adjusted R2

F

df

P

0.0509

0.0353

1.442

.1925

0.1189

2.079

1.7

.1925

0.0507

0.0096

5.293

.0018

0.7942

1.6

.0018

0.1365

0.0614

2.225

.0678

0.3607

1.6

.0678

−0.0897
0.3174

0.0123
0.1064

−7.312
2.984

.0000
.0063

0.6986

32.29

2.25

1.2E-07

−0.0826
0.0447

0.0128
0.0135

−6.470
3.311

.0000
.0032

0.6925

28.03

2.22

8.9E-07

−0.0836
0.0449

0.0152
0.0172

−5.506
2.611

.0000
.0172

0.6369

19.41

2.19

2.6E-05

−0.0060
11.8219

0.0011
2.1569

−5.532
5.481

.0000
.0000

0.5788

15.43

2.19

.0001

−0.0850
0.5046

0.0140
0.1998

−6.060
2.526

.0000
.0206

0.6714

22.46

2.19

9.9E-06

−0.1301
110.5561
−0.0552

0.0213
51.4954
0.0258

−6.108
2.147
−2.141

.0000
.0421
.0426

0.7122

23.27

3.24

2.8E-07

11.1933
−0.0056

1.5533
0.0008

7.206
−7.179

.0000
.0000

0.6753

29.08

2.25

3.0E-07

Estimate

remained robust to various categorization protocols, and
various metrics of cannabis use.
An OR of 1.27 (95% CI = 1.19-1.37) was calculated
for high compared with low cannabis use provinces with
an attributable risk in high cannabis use provinces of
16.52% (95% CI = 12.22% to 20.62%).
As such it would appear from this analysis that the
different patterns in cannabis consumption across
Canada may well explain the east-west gradient of
NTDs, which has long been known and has long been of
interest to neonatal epidemiologists.
Calculations performed in the present work indicate
that the rate of ETOPFA across Canada increased
between 1991 and 2007 from a mean of 32.3% to 43.2%.
The detailed analysis of NTD rates in Canada of De
Wals et al1 included ETOPFA data and showed that a
reduction in NTD rate could be demonstrated when

28.02
4.949

ETOPFA data were included. However, Gilbert and colleagues,20 writing several years later, presumably with
access to much of the data of the earlier study, felt that
they could not say with any certainty how much of the
decline in NTD rates were due to rising ETOPFA rates
and how much was due to folate supplementation. The
present work does not have access to sufficient data to
comment on this interesting dilemma.
The greatest drop in Canada NTD rates occurred in
high-risk provinces after folate supplementation.1 In
Australia this also happened and a dramatic drop in
indigenous Australian Aborigines was also documented
following folate supplementation.37
Beyond the fascinating pattern of epidemiology,
which has been uncovered by the above statistical calculations, one of the most intriguing aspects of this study is
the obvious gaps in the data in relation to the Canadian
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Figure 3. Neural tube defect (NTD) rates by cannabis metrics. (A) NTD rate by last year cannabis use percentage. (B) NTD
rates by age of cannabis initiation. (C) NTD rates by cannabis index (= last year cannabis use/age of initiation).

territories. The maps in Figure 1 clearly show that the
data tabled provide no data whatsoever for the territories
of Nunavut, Yukon, and Northwest and these fascinating
circumpolar parts of arctic Canada remain undefined in
this regard.
Other reports define high rates of total congenital
anomalies, congenital heart disease, Down’s syndrome,
orofacial clefts, and gastroschisis in Nunavut, most of
which are statistically significantly elevated above the

national rates,35 together with high rates of premature
birth, infant mortality, and post-neonatal death elevated
3 times and more above the national average.21 One
might realistically conjecture, therefore, that when the
numbers become available high rates of NTD may also
be shown in such remote northern regions. Nunavut area
is also described as having very high rates of chronic
hunger, homelessness, poverty, violent crime, suicide,
substance abuse, and sexually transmissible disease.38
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Table 2. Linear Regressions of Total NTD Rates Including Estimated ETOPFA Rates.
Parameter Analyses
Input Parameters
Rate ~ year * cannabis use, 2015
Cannabis use (annual)
Year: cannabis use (annual)
Rate ~ year * age initiation
Age of initiation
Year: age of initiation
Rate ~ Year * cannabis index
Cannabis index
Year: cannabis index
Rate ~ year * cannabis use, 2018
Cannabis use (3 months)
Year: cannabis use (3 months)

Model Parameters

Estimate

SD

t Value

Pr(>|t|)

Adjusted R2

F

df

P

7.2497
−0.0036

1.4232
0.0007

5.094
−5.069

.0000
.0000

0.5459

16.03

2.23

4.4E-05

10.0201
−0.0050

2.3703
0.0012

4.227
−4.242

.0004
.0004

0.4210

9.00

2.20

.0016

106.0551
−0.0528

22.5859
0.0113

4.696
−4.672

.0001
.0001

0.5427

14.05

2.20

.0002

9.4836
−0.0047

1.6749
0.0008

5.662
−5.650

.0000
.0000

0.5282

16.67

2.26

2.2E-05

Abbreviations: NTD, neural tube defect; ETOPFA, early termination of pregnancy for anomaly.

Clearly untangling this complex etiological web of
potential causes in the challenging climate of the arctic
north among a scattered population is a task that would
require considerable resources and dedication.
In considering this bewildering array of complex
psychosocial adversity, the present studies would
strongly suggest that cannabis should not be forgotten as
a potential cause. Indeed it is reported that the use of
cannabis by many adult age groups is virtually holoendemic in this region.39 It would seem to us that filling in
these datasets would have far-reaching implications
potentially well beyond those relating to circumpolar
health.
Given robust previous results from leading US
schools of public health linking increasingly liberal legislative paradigms with increased cannabis use,40 the
present findings must raise concerns that increased cannabis use in Canada related to cannabis legalization in
that nation may be shown in time to be associated with
unforeseen trends in NTDs among other congenital
defects.
While the effect demonstrated in this article is at the
level of a statistical association it achieves considerable
importance in light of the numerous documented mechanistic pathways linking cannabis with multiple mechanisms of teratogenesis. Space precludes a detailed
exploration of this subject in this forum, but the following comments may form a useful point of departure for
future workers. It is known that NTDs represent failure
of closure of the embryonic neural tube usually at its
upper and lower ends. Therefore, pathways that impede
cell growth may be implicated. Cannabis has been
shown on proteomic screen to interfere with actin and
tubulin synthesis.41 Actin is a key molecule for the

cytoskeleton involved in cell signaling and cell shape
change in cell division and cell migration. Tubulin is the
monomer from which microtubules form, which form
the rails of cell division. Cannabis has long been known
to test positive in the micronuclear assay and this is
believed to be on the basis of its interference with microtubular function.42-44 Cannabis also perturbs notch signaling, which is a key morphogen for both embryonic
neuraxis and cardiovascular formation.45,46
Closure of the neural tube initiates at the level of the
human hindbrain on post-fertilization day 22 and proceeds bidirectionally cephalad and caudal. It also initiates from the rostral neuropore bidirectionally. Closure
occurs at the anterior neuropore on day 24 and over the
sacrum on day 26.2 Over 200 genes involved in pathways such as cytoskeletal regulation, cell proliferation,
transcriptional control, one carbon transfer, epigenetic
regulation, and interference with sphingosine phosphate
metabolism (by the fungal metabolite fumonisin) have
been implicated.2 Molecular signaling pathways including hedgehog, bone morphogenetic proteins, and retinoid signaling have also been implicated.2 Interestingly,
cannabinoids interact with and inhibit each of these
major pathways with cannabinoid-hedgehog,47 cannabinoid-bone morphogenetic proteins (both directly and by
vanilloid mediation),48 and cannabinoid-retinoid interactions49-52 having been previously described.
Cannabis adversely affects robo/slit signaling, which
is a key receptor ligand pair that has major dual actions
in brain and nerve formation.53 Low levels of robo are
key to the hyperproliferation of subventricular zone
embryonic neuroblasts and formation of the large
human neocortex.54,55 And robo/slit pairs also form key
guidance signals for both axon guidance and vascular
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sprouting and direction.46 Slit2 is also a tumor suppressor.56 Cannabis interferes with neurexin and neuroligin
synthesis and signaling this receptor ligand pair forms
the basic scaffold of the neuronal synapse and plays a
key role in synaptic formation and organization.57,58
Cannabinoids have numerous immune interactions and
immune activity is a key sculptor of the embryonic and
developing neuraxis.59 Cannabis has widespread epigenetic actions with effects particularly on the brain,
immune systems, and sperm.60-64 Interestingly, folic acid
also works epigenetically by acting as a methyl donor in
N-methylation reactions for DNA and histones via
S-adenosyl-methionine.65 Cannabis acts via at least 7
receptors in the body.59 The type 1 cannabinoid receptor
(CB1R) is widely distributed in many tissues including
brain from very early in fetal life and is thus likely to
have downstream consequences.66,67 Cannabinoid signaling via CB1Rs is a key regulator of cerebral microvascular function and is directly responsible for the
BOLD signal seen on functional magnetic resonance
imaging with neuronal activity.68 The brain’s microvasculature forms a key regulator of brain neurogenic
niches.67,69-71 Brain formation and circuit wiring is
highly dependent on neuronal activity. In that cannabis
is well known to suppress neuronal firing, this implies
that it will have major morphological and long-term
developmental consequences. And CB1Rs are also
found at moderate density in bone.72,73
Cannabinoids are also highly toxic to eggs and spermatids.74-78 Both ova and mature spermatids lack most
of the molecular genetic machinery to repair DNA damage. The very real possibility exists therefore that damage to nonrenewable ova may be long term or even
permanent.
Interestingly, prenatal cannabis exposure was
recently shown to affect the methylation status of 4
genes involved in Wnt signaling, which is a major body
morphogen, namely, 3A, 5A, 9A, and 10A.63 Wnt signaling has been shown to control closure of the anterior
neuropore,79 a finding which may relate directly to the
elevated risk of encephalocoele which has been linked
epidemiologically with prenatal cannabis use.80
In summary, while it is often said that cannabis is a
“natural product,” the reality is that it has been well detmonstrated in botanical science that cannabinoids form
part of a potent plant defense mechanism against both
other plants—including other cannabis plants—and animals.81,82 That is to say cannabinoids are in fact a natural
plant poison.
The strengths of this study are that it takes national
and publicly available data from 2 leading sources, uses
2 metrics of cannabis consumption and 2 categorization
protocols to conduct a secondary analysis of national

data at the provincial level. The analyses are simple and
straightforward and are clearly in close accordance with
the demonstrated graphical and map displays. Many of
the probability levels reported are at high or very high
levels of statistical significance.
Most of the limitations of this study relate to its
design as an ecological secondary analysis. Individual
case-control data were not available to this study.
Territory congenital anomaly and covariate data are not
yet publicly available for Canada, and that is likely to be
some of the most important data of all. It has not been
possible here to take into account any of the covariates
such as race, diet, and education that might be studied in
a larger investigation as these data were not available for
our analysis. Given that much of the north of Canada is
very cold and dark most of the year, dietary factors may
be very important, as may genetic allele frequencies of
native and indigenous people groups. From a methodological perspective, it is important to note that to simply add in covariates such as ethnicity, in the presence of
well-documented and adequately substantiated major
racial differences in the prevalence of drug use, is to
make an opposite error of over-controlling and in fact
erroneously regressing out important differences. In this
regard, advanced statistical techniques such as generalized 2-stage regression with appropriate instrumental
variables may be a more versatile tool. Ideally geospatiotemporal models at high geographic resolution, which
take into account all of these various factors using
appropriate adjustment and advanced statistical methods, may be most appropriate for future investigations
once a sufficient dataset can be assembled. ETOPFA
data were not available longitudinally, which would be
preferable to conduct a formal study. Notwithstanding
this we see our work as important and path finding and
showing the way for future more detailed and more
complex studies both in Canada and internationally.

Conclusion
The epidemiological relationship that we have demonstrated between cannabis use and NTD incidence within
the context of falling overall NTD rates is interesting,
provocative, and intriguing. The ecological association is
seen in both live born statistics and also in estimates of
the complete dataset including ETOPFA data, which are
important to complete the holistic picture of the true epidemiological incidence of NTDs; it is seen with 2 metrics of cannabis use and with 2 categorization algorithms
for classifying the provinces. Our work is consistent with
earlier reports from the CDC in the United States relating
to the links between cannabis use and the doubled incidence of anencephaly. In the context of multiple known
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molecular mechanistic pathways such compelling and
robust statistical associations necessarily implicate causality. We would be keen to see this relationship studied
in other places along with the all-important applicable
ETOPFA and covariate data preferably in case-control
designs. The arctic regions of Canada are almost certainly of particular importance to the neonatal epidemiology of NTDs with far-reaching and likely global
implications and require further detailed investigation.
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